Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial

• Published in: European heart journal 2014-09, Vol.35 (35), p.2352-2362
• Main Authors: Boriani, Giuseppe, Tukkie, Raymond, Manolis, Antonis S, Mont, Lluis, Pürerfellner, Helmut, Santini, Massimo, Inama, Giuseppe, Serra, Paolo, de Sousa, João, Botto, Giovanni Luca, Mangoni, Lorenza, Grammatico, Andrea, Padeletti, Luigi
• Format: Article
• Language: English
• Subjects: Aged; Atrial Fibrillation - complications; Atrial Fibrillation - mortality; Atrial Fibrillation - therapy; Bradycardia - complications; Bradycardia - mortality; Bradycardia - therapy; Cardiac Pacing, Artificial - adverse effects; Cardiac Pacing, Artificial - methods; Clinical Research; Cost of Illness; Female; Hospitalization - statistics & numerical data; Humans; Kaplan-Meier Estimate; Male; Quality of Life; Risk Factors; Single-Blind Method; Treatment Outcome
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/ehu165

Atrial fibrillation (AF) is a common comorbidity in bradycardia patients. Advanced pacemakers feature atrial preventive pacing and atrial antitachycardia pacing (DDDRP) and managed ventricular pacing (MVP), which minimizes unnecessary right ventricular pacing. We evaluated whether DDDRP and MVP might reduce mortality, morbidity, or progression to permanent AF when compared with standard dual-chamber pacing (Control DDDR). In a randomized, parallel, single-blind, multi-centre trial we enrolled 1300 patients with bradycardia and previous atrial tachyarrhythmias, in whom a DDDRP pacemaker had recently been implanted. History of permanent AF and third-degree atrioventricular block were exclusion criteria. After a 1-month run-in period, 1166 eligible patients, aged 74 ± 9 years, 50% females, were randomized to Control DDDR, DDDRP + MVP, or MVP. Analysis was intention-to-treat. The primary outcome, i.e. the 2-year incidence of a combined endpoint composed of death, cardiovascular hospitalizations, or permanent AF, occurred in 102/385 (26.5%) Control DDDR patients, in 76/383 (19.8%) DDDRP + MVP patients [hazard ratio (HR) = 0.74, 95% confidence interval 0.55-0.99, P = 0.04 vs. Control DDDR] and in 85/398 (21.4%) MVP patients (HR = 0.89, 95% confidence interval 0.77-1.03, P = 0.125 vs. Control DDDR). When compared with Control DDDR, DDDRP + MVP reduced the risk for AF longer than 1 day (HR = 0.66, 95% CI 0.52-0.85, P < 0.001), AF longer than 7 days (HR = 0.52, 95% CI 0.36-0.73, P < 0.001), and permanent AF (HR = 0.39, 95% CI 0.21-0.75, P = 0.004). In patients with bradycardia and atrial tachyarrhythmias, DDDRP + MVP is superior to standard dual-chamber pacing. The primary endpoint was significantly lowered through the reduction of the progression of atrial tachyarrhythmias to permanent AF. NCT00262119.